These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 24582759)

  • 41. The chemokine receptor CCR5 Δ32 allele in natalizumab-treated multiple sclerosis.
    Møller M; Søndergaard HB; Koch-Henriksen N; Sorensen PS; Sellebjerg F; Oturai AB
    Acta Neurol Scand; 2014 Jan; 129(1):27-31. PubMed ID: 23668375
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The use of cytokine signature patterns: separating drug naïve, interferon and natalizumab-treated multiple sclerosis patients.
    O'Connell KE; Mok T; Sweeney B; Ryan AM; Dev KK
    Autoimmunity; 2014 Dec; 47(8):505-11. PubMed ID: 24974887
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Natalizumab (Tysabri) for relapsing multiple sclerosis.
    Med Lett Drugs Ther; 2005 Feb; 47(1202):13-5. PubMed ID: 15711498
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Humoral immune response to influenza vaccine in natalizumab-treated MS patients.
    Vågberg M; Kumlin U; Svenningsson A
    Neurol Res; 2012 Sep; 34(7):730-3. PubMed ID: 22709910
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Induction of systemic TNFalpha in natalizumab-treated multiple sclerosis.
    Khademi M; Stol D; Olsson T; Wallström E
    Eur J Neurol; 2008 Mar; 15(3):309-12. PubMed ID: 18190511
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Spanish consensus on the use of natalizumab (Tysabri(®))--2011.
    Fernández O; García-Merino JA; Arroyo R; Álvarez-Cermeño JC; Arbizu T; Izquierdo G; Saiz A; Olascoaga J; Rodríguez-Antigüedad A; Prieto JM; Oreja-Guevara C; Hernández MA; Montalbán X
    Neurologia; 2012 Sep; 27(7):432-41. PubMed ID: 22078648
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of oral melatonin supplementation on urine and serum melatonin concentrations and quality-of-life measures in persons with relapsing multiple sclerosis.
    Smoot K; Gervasi-Follmar T; Marginean H; Chen C; Cohan S
    Mult Scler Relat Disord; 2024 Oct; 90():105799. PubMed ID: 39126937
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
    Maillart E; Louapre C; Lubetzki C; Papeix C
    Mult Scler; 2014 Apr; 20(4):505-9. PubMed ID: 24367037
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Effectiveness and safety of natalizumab in multiple sclerosis: data of the first five years from the TOP (Tysabri Observational Program)].
    Magdolna S
    Ideggyogy Sz; 2014 May; 67(5-6):211-2. PubMed ID: 25087382
    [No Abstract]   [Full Text] [Related]  

  • 50. Failure of natalizumab to prevent relapses in neuromyelitis optica.
    Kleiter I; Hellwig K; Berthele A; Kümpfel T; Linker RA; Hartung HP; Paul F; Aktas O;
    Arch Neurol; 2012 Feb; 69(2):239-45. PubMed ID: 22332191
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis--a prospective, non-randomized pilot study.
    Portaccio E; Stromillo ML; Goretti B; Hakiki B; Giorgio A; Rossi F; De Leucio A; De Stefano N; Amato MP
    Eur J Neurol; 2013 Jun; 20(6):986-90. PubMed ID: 23057658
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
    Bartt RE
    Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS.
    Balcer LJ; Galetta SL; Polman CH; Eggenberger E; Calabresi PA; Zhang A; Scanlon JV; Hyde R
    J Neurol Sci; 2012 Jul; 318(1-2):119-24. PubMed ID: 22521274
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab.
    Blinkenberg M; Sellebjerg F; Leffers AM; Madsen CG; Sørensen PS
    Mult Scler; 2013 Aug; 19(9):1226-9. PubMed ID: 23508652
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
    Rudick RA; Stuart WH; Calabresi PA; Confavreux C; Galetta SL; Radue EW; Lublin FD; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA; Sandrock AW;
    N Engl J Med; 2006 Mar; 354(9):911-23. PubMed ID: 16510745
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis.
    Prosperini L; Giannì C; Leonardi L; De Giglio L; Borriello G; Galgani S; Pozzilli C; Gasperini C
    Mult Scler; 2012 Jan; 18(1):64-71. PubMed ID: 21828195
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis.
    O'Connor PW; Goodman A; Kappos L; Lublin FD; Miller DH; Polman C; Rudick RA; Aschenbach W; Lucas N
    Neurology; 2011 May; 76(22):1858-65. PubMed ID: 21543733
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cerebrospinal fluid biomarkers of β-amyloid metabolism in multiple sclerosis.
    Augutis K; Axelsson M; Portelius E; Brinkmalm G; Andreasson U; Gustavsson MK; Malmeström C; Lycke J; Blennow K; Zetterberg H; Mattsson N
    Mult Scler; 2013 Apr; 19(5):543-52. PubMed ID: 23069872
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis.
    Warnke C; Mausberg AK; Stettner M; Dehmel T; Nekrich L; Meyer zu Horste G; Hartung HP; Fogdell-Hahn A; Adams O; Kieseier BC
    Neurology; 2013 Oct; 81(16):1400-8. PubMed ID: 24049136
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Trajectory of fatigue severity in natalizumab treated multiple sclerosis patients.
    Yildiz M; Tettenborn B; Borgwardt S
    Clin Neurol Neurosurg; 2013 Jul; 115(7):902-3. PubMed ID: 23021201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.